论文部分内容阅读
目的通过直肠癌患者在化疗前和化疗结束时的血常规检验指标的变化以及其与HLA-DRB1、DQB1多态性的关联,以期找到直肠癌化疗副损伤的相关的基因。方法选取78例直肠癌患者,采用多聚酶链反应-序列特异性引物(PCR-SSP)法检测其HLA-DRB1、DQB1的多态性。同时检测直肠癌患者化疗前和化疗结束时的血常规检验指标,包括:WBC、RBC、HGB、PLT、NEUT#、LYM#等。结果 HLA-DRB1*07有可能是化疗对RBC损伤的抵抗基因;HLA-DRB1*08有可能是化疗对LYM#损伤的敏感基因;HLA-DRB1*09有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DRB1*12有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DQB1*02有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DQB1*05有可能是化疗对HGB损伤的抵抗基因,同时HLA-DQB1*05也可能是化疗对NEUT#损伤的敏感基因;HLA-DQB1*07有可能是化疗对RBC、HGB损伤的抵抗基因。结论 HLA可能是肿瘤化疗副损伤的标志性基因。
OBJECTIVE: To investigate the association of HLA-DRB1 and DQB1 polymorphisms in patients with rectal cancer before and at the end of chemotherapy with the aim of finding relevant genes for chemotherapy-induced side effects of rectal cancer. Methods Totally 78 patients with rectal cancer were enrolled. The polymorphisms of HLA-DRB1 and DQB1 were detected by polymerase chain reaction-sequence-specific primers (PCR-SSP). At the same time, the blood test indexes of patients with rectal cancer before chemotherapy and at the end of chemotherapy were detected, including WBC, RBC, HGB, PLT, NEUT # and LYM #. Results HLA-DRB1 * 07 may be a resistance gene for chemotherapy-induced RBC injury. HLA-DRB1 * 08 may be a sensitive gene for chemotherapy-induced LYM # injury. HLA-DRB1 * 09 may be the resistance of chemotherapy to RBC and HGB injury HLA-DRB1 * 12 may be the resistance gene of chemotherapy for RBC and HGB injury; HLA-DQB1 * 02 may be the resistance gene of chemotherapy for RBC and HGB injury; HLA-DQB1 * 05 may be the result of chemotherapy for HGB injury HLA-DQB1 * 05 may also be a sensitive gene for the chemotherapy-induced NEUT # injury. HLA-DQB1 * 07 may be a resistance gene for the chemotherapy of RBC and HGB injury. Conclusion HLA may be a landmark gene for chemotherapy-induced side effects.